The Congress of Neurological Surgeons (CNS) has announced that Elon Musk will be featured in its 2024 Annual Meeting at the George R. Brown Convention Center in Houston, Texas. Musk will be discussing Neuralink’s projects during his interview.
The CNS Annual Meeting is one of the largest meetings in the field of neurosurgery. As noted by the organization on its official website, this year’s event would “reflect on the historical journey and current state of neurosurgery, using a fresh lens to synthesize insights and chart a course for an enlightened future.”
Musk’s participation at the 2024 CNS Annual Meeting is quite unsurprising. His work with Neuralink, after all, effectively puts him at the forefront of the brain-computer interface (BCI) industry. The CNS noted that Musk would be attending the event virtually, and he would be discussing a variety of topics with CNS President Dr. Alexander Khalessi.
Breaking news! @elonmusk, Founder and CEO of @neuralink will be the 2024 CNS Michael L.J. Apuzzo Lecturer on Creativity and Innovation. Don’t miss this blended interactive virtual session. Have a question you’d like to ask Mr. Musk? Not too late to register for the CNS meeting! pic.twitter.com/oRiI93YnEB
— CNS (@CNS_Update) September 23, 2024
“The session will focus on the challenges of building and scaling brain-computer interfaces (BCI), Neuralink’s innovative approaches to addressing these challenges for patients in need, and the future direction of this emerging field,” the CNS wrote.
Neuralink only has a couple of human patients today, but the potential of the company’s devices has become notable. The company currently offers one product, Telepathy, which enables people with paralysis to control tech devices such as computers or smartphones with their mind. Neuralink has two patients so far, both of whom seem to be adjusting very well to the capabilities of their brain implants.
Neuralink’s later products are just as, if not more ambitious than Telepathy. As noted by Elon Musk, Neuralink’s next product would be called “Blindsight,” which would be aimed at restoring vision in patients who have lost sight. Reports have indicated that Blindsight has received a “breakthrough device” designation from the FDA.
Don’t hesitate to contact us with news tips. Just send a message to simon@teslarati.com to give us a heads up.
